|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wahid B, Ali A, Rafique S and Idrees M:
New insights into the epigenetics of hepatocellular carcinoma.
Biomed Res Int. 2017:16095752017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herceg Z and Paliwal A: Epigenetic
mechanisms in hepatocellular carcinoma: How environmental factors
influence the epigenome. Mutat Res. 727:55–61. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Villanueva A, Hoshida Y, Battiston C,
Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M,
Kumada H, et al: Combining clinical, pathology, and gene expression
data to predict recurrence of hepatocellular carcinoma.
Gastroenterology. 140(1501–1512): e22011.
|
|
5
|
Walker MG: Drug target discovery by gene
expression analysis: Cell cycle genes. Curr Cancer Drug Targets.
1:73–83. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang N and Pati D: Sororin is a master
regulator of sister chromatid cohesion and separation. Cell Cycle.
11:2073–2083. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang N and Pati D: C-terminus of Sororin
interacts with SA2 and regulates sister chromatid cohesion. Cell
Cycle. 14:820–826. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rankin S, Ayad NG and Kirschner MW:
Sororin, a substrate of the anaphase-promoting complex, is required
for sister chromatid cohesion in vertebrates. Mol Cell. 18:185–200.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nishiyama T, Sykora MM, Huis in 't Veld
PJ, Mechtler K and Peters JM: Aurora B and Cdk1 mediate Wapl
activation and release of acetylated cohesin from chromosomes by
phosphorylating Sororin. Proc Natl Acad Sci USA. 110:13404–13409.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nishiyama T, Ladurner R, Schmitz J, Kreidl
E, Schleiffer A, Bhaskara V, Bando M, Shirahige K, Hyman AA,
Mechtler K, et al: Sororin mediates sister chromatid cohesion by
antagonizing Wapl. Cell. 143:737–749. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nguyen MH, Koinuma J, Ueda K, Ito T,
Tsuchiya E, Nakamura Y and Daigo Y: Phosphorylation and activation
of cell division cycle associated 5 by mitogen-activated protein
kinase play a crucial role in human lung carcinogenesis. Cancer
Res. 70:5337–5347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Showe MK, Kossenkov AV and Showe LC: The
peripheral immune response and lung cancer prognosis.
Oncoimmunology. 1:1414–1416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang IW, Lin VC, He HL, Hsu CT, Li CC, Wu
WJ, Huang CN, Wu TF and Li CF: CDCA5 overexpression is an indicator
of poor prognosis in patients with urothelial carcinomas of the
upper urinary tract and urinary bladder. Am J Transl Res.
7:710–722. 2015.PubMed/NCBI
|
|
14
|
Tokuzen N, Nakashiro K, Tanaka H, Iwamoto
K and Hamakawa H: Therapeutic potential of targeting cell division
cycle associated 5 for oral squamous cell carcinoma. Oncotarget.
7:2343–2353. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Z, Shen M and Zhou G: Upregulation
of CDCA5 promotes gastric cancer malignant progression via
influencing cyclin E1. Biochem Biophys Res Commun. 496:482–489.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen Z, Yu X, Zheng Y, Lai X, Li J, Hong
Y, Zhang H, Chen C, Su Z and Guo R: CDCA5 regulates proliferation
in hepatocellular carcinoma and has potential as a negative
prognostic marker. Onco Targets Ther. 11:891–901. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sia D, Villanueva A, Friedman SL and
Llovet JM: Liver cancer cell of origin, molecular class, and
effects on patient prognosis. Gastroenterology. 152:745–761. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dhayat SA, Hüsing A, Senninger N, Schmidt
HH, Haier J, Wolters H and Kabar I: Circulating microRNA-200 family
as diagnostic marker in hepatocellular carcinoma. PLoS One.
10:e1400662015. View Article : Google Scholar
|
|
19
|
Bagi CM and Andresen CJ: Models of
hepatocellular carcinoma and biomarker strategy. Cancers.
2:1441–1452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang W, Jia WD, Hu B and Pan YY: RAB10
overexpression promotes tumor growth and indicates poor prognosis
of hepatocellular carcinoma. Oncotarget. 8:26434–26447.
2017.PubMed/NCBI
|
|
21
|
Klingenberg M, Matsuda A, Diederichs S and
Patel T: Non-coding RNA in hepatocellular carcinoma: Mechanisms,
biomarkers and therapeutic targets. J Hepatol. 67:603–618. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Khan FS, Ali I, Afridi UK, Ishtiaq M and
Mehmood R: Epigenetic mechanisms regulating the development of
hepatocellular carcinoma and their promise for therapeutics.
Hepatol Int. 11:45–53. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kato T, Lee D, Wu L, Patel P, Young AJ,
Wada H, Hu HP, Ujiie H, Kaji M, Kano S, et al: SORORIN and PLK1 as
potential therapeutic targets in malignant pleural mesothelioma.
Int J Oncol. 49:2411–2420. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tokuzumi A, Fukushima S, Miyashita A,
Nakahara S, Kubo Y, Yamashita J, Harada M, Nakamura K, Kajihara I,
Jinnin M and Ihn H: Cell division cycle-associated protein 1 as a
new melanoma-associated antigen. J Dermatol. 43:1399–1405. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kobayashi Y, Takano A, Miyagi Y, Tsuchiya
E, Sonoda H, Shimizu T, Okabe H, Tani T, Fujiyama Y and Daigo Y:
Cell division cycle-associated protein 1 overexpression is
essential for the malignant potential of colorectal cancers. Int J
Oncol. 44:69–77. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi R, Zhang C, Wu Y, Wang X, Sun Q, Sun
J, Xia W, Dong G, Wang A, Jiang F and Xu L: CDCA2 promotes lung
adenocarcinoma cell proliferation and predicts poor survival in
lung adenocarcinoma patients. Oncotarget. 8:19768–19779.
2017.PubMed/NCBI
|
|
27
|
Adams MN, Burgess JT, He Y, Gately K,
Snell C, Zhang SD, Hooper JD, Richard DJ and O'Byrne KJ: Expression
of CDCA3 is a prognostic biomarker and potential therapeutic target
in non-small cell lung cancer. J Thorac Oncol. 12:1071–1084. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong
Q, Qin L, Wu X, Zheng Y, Yang Y, et al: Identification of miRNomes
in human liver and hepatocellular carcinoma reveals miR-199a/b-3p
as therapeutic target for hepatocellular carcinoma. Cancer Cell.
19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng
IO, Sun H, Qin L, Qiu S, Lee JM, et al: Hepatic RIG-I predicts
survival and interferon-alpha therapeutic response in
hepatocellular carcinoma. Cancer Cell. 25:49–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Burotto M, Chiou VL, Lee JM and Kohn EC:
The MAPK pathway across different malignancies: A new perspective.
Cancer. 120:3446–3456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang S, Huang X, Li Y, Lao H, Zhang Y,
Dong H, Xu W, Li JL and Li M: RN181 suppresses hepatocellular
carcinoma growth by inhibition of the ERK/MAPK pathway. Hepatology.
53:1932–1942. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schmidt CM, McKillop IH, Cahill PA and
Sitzmann JV: Increased MAPK expression and activity in primary
human hepatocellular carcinoma. Biochem Biophys Res Commun.
236:54–58. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsuboi Y, Ichida T, Sugitani S, Genda T,
Inayoshi J, Takamura M, Matsuda Y, Nomoto M and Aoyagi Y:
Overexpression of extracellular signal-regulated protein kinase and
its correlation with proliferation in human hepatocellular
carcinoma. Liver Int. 24:432–436. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vara Fresno JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Alessi DR, Andjelkovic M, Caudwell B, Cron
P, Morrice N, Cohen P and Hemmings BA: Mechanism of activation of
protein kinase B by insulin and IGF-1. EMBO J. 15:6541–6551.
1996.PubMed/NCBI
|
|
38
|
Schmitz KJ, Wohlschlaeger J, Lang H,
Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR,
Schmid KW and Baba HA: Activation of the ERK and AKT signalling
pathway predicts poor prognosis in hepatocellular carcinoma and ERK
activation in cancer tissue is associated with hepatitis C virus
infection. J Hepatol. 48:83–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nakanishi K, Sakamoto M, Yamasaki S, Todo
S and Hirohashi S: Akt phosphorylation is a risk factor for early
disease recurrence and poor prognosis in hepatocellular carcinoma.
Cancer. 103:307–312. 2005. View Article : Google Scholar : PubMed/NCBI
|
